Osseon Therapeutics completes first Osseoplasty procedures in Europe

NewsGuard 100/100 Score

Osseon Therapeutics Inc. today announced it has completed its first Osseoplasty™ procedures in Europe. The procedures were performed in Milan, Italy.

Teaming with its European distributor MBA Incorporado, SL, the largest independent medical device distributor in Europe, Osseoplasty cases are also scheduled to begin in the next weeks in the United Kingdom, Germany and Spain.

Osseon's product line features the Osseoflex™ (steerable and curvable needle) and Osseoperm™ (bone cement). These products combine to form a unique new procedure termed Osseoplasty to treat painful acute fractures of the vertebrae seen increasingly in older individuals with osteoporosis and osteometastatic injuries.

Osseoflex can access the entire vertebral body from a singular unipedicular percutaneous access point. The Osseoplasty system is unique for its delivery of optimal viscosity cement and precise cement placement through the highly maneuverable Osseoflex needle. The Osseoplasty procedure provides rapid stabilization of vertebral fractures and significant pain relief on the day of treatment.

MBA will distribute Osseon's products to physicians and hospitals throughout the European Union, including the United Kingdom, Germany, Spain, Portugal, Italy, Greece, Austria, Switzerland, Scandinavia, Turkey and Germany.

According to John Stalcup, Ph.D., CEO of Osseon, "MBA has an excellent and long-established international reputation for marketing and distributing medical devices for independent innovators and an unparalleled reputation for customer service. The partnership between MBA and Osseon represents a major step forward in the expansion of Osseoplasty into the key markets of Europe."

Source:

Osseon Therapeutics, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Natural killer cells lead the charge in cancer treatment innovation